In recent industry news, AAV gene therapies are gaining momentum, with groundbreaking achievements like RegenxBio’s RGX-121 trial for Hunter syndrome, demonstrating significant improvements in neurodevelopmental skills. The global AAV therapy […]

Advancing Curative Therapies for Autoimmune Diseases  Building on the success of last year’s meeting, the 8th Antigen-Specific Immune Tolerance Summit will bring together 120+ end-to-end experts in immune tolerance for autoimmune diseases. […]

Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources. This, along with […]

4th mRNA Analytical Development & Quality Control Summit | February 25-27, 2025 Excitement for mRNA therapeutics continues, as RNA technologies are awarded the Nobel Prize for the second year running. […]

The radiopharmaceutical race is on and pharma leaders such as AstraZenca, BMS , Eli Lilly, Novartis and Sanofi are not getting left behind. Bolstering discovery pipelines through acquisitions of preclinical […]

2025 is shaping up to be the ‘bounce back’ year for natural killer therapy. For the first time we are seeing efficacious in-patient data, expansion into autoimmune disease, and combination […]

Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval, the field has seen a surge […]

In the current cell therapy landscape, where funding is tight and clinical development a priority, developing robust potency assays is critical to avoid costly delays. Introducing the 4th Cell Therapy Potency […]

Expanded Access Programs (EAPs) are increasingly recognized as an ethical imperative in modern healthcare. More companies are opening EAPs to provide critical therapies to patients who would otherwise lack access. […]

The field of conjugatable drugs is advancing at a rapid pace, with major collaborations like Nurix & Pfizer for antibody-degrader conjugates and Bicycle & Novartis for radiopharmaceuticals, which paves the […]

With 14 new gene therapy approvals in the last 18 months, billion-dollar collaborations, and the development of treatments for more common conditions, the gene therapy field is rapidly gaining momentum […]

In today’s complex drug development landscape, leveraging biophysical tools to unravel the molecular and target engagement intricacies of drug candidates is more critical than ever for successfully advancing molecules through […]

With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics. Whether for nose-to-brain delivery or emergency use, nasal delivery is opening a […]

The 2nd Peptide-Based Therapeutics Summit will return to Boston in April 2025, bringing together over 80 experts in peptide computational science, medicinal chemistry, and formulation to discuss the latest advancements […]

LEAP HR: Life Sciences West is your chance to explore how leading and emerging biopharma organizations are navigating industry volatility and preparing for the workforce of tomorrow. As the sector […]

With the autoimmune wave breathing financial life back into the allogeneic space, and a growing number of oncology pipelines entering the clinic, the allogeneic community are eagerly anticipating what lies […]